OliPass was founded in 2006 to develop a druggable and affordable oligonucleotide platform technology, i.e. “OliPass™ Oligonucleotide”.

OliPass™ Oligonucleotide is a novel class of peptide nucleic acid derivatives rationally designed to possess good cell permeability and ultra-potent therapeutic activity of RNA modulation. The good cell permeability of OliPass™ Oligonucleotide allows in vitro gene function to be flexibly modulated at sub-attomolar (10-18M) concentration. OliPass™ Oligonucleotide does not require any invasive formulations for therapeutic purposes.